% | $
Quotes you view appear here for quick access.

Cyclacel Pharmaceuticals, Inc. (CYCC) Message Board

  • brianisthebest1111 brianisthebest1111 Apr 5, 2013 5:08 PM Flag

    I want you to relfect on these two statements

    This was as of last October in regards to the MDS trial:

    Updated mature survival data will be reported in late 2012 or early 2013. Cyclacel is developing a pivotal development plan for the indication of second-line MDS to present to regulatory authorities.

    And from the Spirio during the CC:

    We plan to report updated survival data from our ongoing MDS program as soon as mature follow-up is reached.

    What caused the timeline change? Obviously the remaining patients are living longer than expected. No other explanation when the primary endpoint is 1-year survival.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.75-0.03(-3.83%)Jul 6 4:00 PMEDT